Sponsored, no-charge genetic testing and counseling for chronic kidney disease

To facilitate diagnosis of several rare forms of chronic kidney disease (CKD), Reata Pharmaceuticals and Invitae have partnered to offer sponsored, no-charge genetic testing and counseling for patients with CKD.

Genetic testing can improve diagnosis and treatment

Early detection and accurate diagnosis are critical to slowing the progression of chronic kidney disease (CKD).1,3-5 CKD often has no symptoms in stages 1-3 and can go undetected until the disease is advanced (stages 4-5).
Recent advances in genetics have enabled greater clinical insights into the classification of inherited CKD. Beyond diagnostic confirmation, this deeper knowledge can provide insights into the natural progression of a patient’s diseases so you can make fully formed healthcare decisions.

The benefits of genetic testing include:

  • Identify risk of disease for patients and their family members
  • Unlock precise genetic information that can guide next steps
  • Help assess prognosis and inform disease management strategies
  • Connect patients to support services including advocacy organizations
1 in 10
In a recent analysis of 3,315 patients with CKD, approximately 1 in 10 had a genetic cause.3
Significantly more likely
Patients with a family history or whose kidney disease had no known origin were significantly more likely to have a genetic variant.3
>1 in 3
The findings reclassified the disease or provided a cause previously undiagnosed for more than 1 in 3 of patients with a genetic basis of disease.3
30%
Genetic variants associated with rare diseases, such as Alport syndrome, were found with much greater frequency (30%) than previously reported.3

About the KIDNEYCODE program

(19 genes in the panel)

The panel

KIDNEYCODE offers genetic testing with the Invitae Progressive Renal Disease Panel, which includes 18 genes that are known to be associated with chronic kidney disease, including Alport syndrome, FSGS, and one form of ADPKD (PKD2).

Program eligibility

To be eligible for this program, individuals are required to have:
  • At least one of the following:
    • Suspected or biopsy-confirmed diagnosis of Alport syndrome or focal segmental glomerulosclerosis (FSGS)
    • Family member with a suspected or biopsy-confirmed diagnosis of Alport syndrome or focal segmental glomerulosclerosis (FSGS)
or
  • eGFR ≤ 90mL/min/1.73m2  and  at least one of the following:
    • Hematuria
    • Family history of kidney disease

How to order

1. Submit an order

To place your online order, click here and follow the on-screen prompts.

To place a paper-based order, download the paper order form and include it in the specimen box. 

2. Collect a specimen

If a specimen collection kit was not ordered during the online ordering workflow, order a blood, buccal, or saliva collection kit here
Please view specimen and shipping requirements for important information, and be sure to include the completed requisition form in the kit with the specimen. 

3. Receive results

On average, results are available 10-21 days after Invitae receives the specimen. You will receive a notification email once the test results are ready.
Log in to view the status of your online order. 

Family variant testing for familial insights

If a positive result is identified, testing for your patient’s family members is available.

Simply follow the ordering instructions, selecting only the gene(s) you are interested in testing for the family member. The partner code will automatically be added with the order.

LEARN MORE

Post-test genetic counseling

Individuals tested through the KIDNEYCODE program are eligible for post-test genetic counseling to help them understand their results. This service is provided through GeneMatters, a third-party genetic counseling service, and is made available by Invitae at no charge as part of the program.
To schedule a genetic counseling appointment, please contact GeneMatters at 1-866-741-5331 or schedule online using partner code: CKD.

*For this program, blood, saliva, and buccal (cheek) swab samples are accepted; gDNA samples are not. For additional information, please see Invitae's specimen and shipping requirements.

Disclaimer

While Reata provides certain financial support for this program, tests and services are performed by independent third parties. Healthcare professionals must confirm that patients satisfy certain criteria to use the program. Reata receives certain aggregated and de-identified data from this program, but at no time does Reata receive individually identifiable patient information. Reata receives certain contact information for healthcare professionals who use this program. Genetic testing and counseling are available in the US only. Healthcare professionals and patients who use this program have no obligation to recommend, purchase, order, prescribe, promote, administer, use or support any Reata product. This program does not replace directly or indirectly the professional medical advice of a treating physician or healthcare professional. All treatment related decisions must be determined by a physician.

References

  1. The facts about chronic kidney disease. National Kidney Foundation website. www.kidney.org/atoz/content/about-chronic-kidney-disease#facts. Accessed July 2019.
  2. Kidney Disease Statistics for the United States/Fast Facts. National Institute of Diabetes and Digestive and Kidney Diseases website. www.niddk.nih.gov/health-information/health-statistics/kidney-disease. Accessed July 2019.
  3. Groopman EE, Marasa M, Cameron-Christie S et al. Diagnostic utility of exome sequencing for kidney disease. NEJM. 2018;doi:10.1056.
  4. Levin A, Tonelli M, Bonventre J et al. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet. 2017;390:1888-1917.
  5. U.S. Department of Health and Human Services. Remarks to the National Kidney Foundation. March 4, 2019. Washington, DC.
  6. Gribouval O, Boyer O, Hummel A et al. Identification of genetic causes for sporadic steroid-resistant nephrotic syndrome in adults. Kidney Int. 2018:94(5):1013-1022.